Can zapping residual lung cancer spots extend remission?
NCT ID NCT07822984
First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time
Summary
Researchers are testing whether adding focused radiation to the few remaining cancer spots helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their disease getting worse. Participants first receive a third-generation EGFR-targeted drug plus platinum-based chemotherapy. Those whose cancer has not progressed but still shows a small number of leftover spots are randomly assigned to either continue maintenance therapy alone or also receive stereotactic radiotherapy to those spots. The main measure is how long participants live before their cancer progresses.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- stereotactic radiotherapy added to third-generation EGFR tyrosine kinase inhibitor plus pemetrexed maintenance therapy
- What this could lead to
- If it works, this could give people with advanced EGFR-mutant lung cancer a way to extend the time before their disease progresses by targeting the few remaining spots with focused radiation.
- What could go wrong
- The trial may show that adding radiation does not delay progression or improve survival compared with maintenance therapy alone. Radiation to the chest or brain carries risks of tissue damage, inflammation, and other side effects, and results from this trial may not apply to all patients with this cancer type.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 374 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed non-small cell lung cancer. * Clinical stage IV disease according to the AJCC 9th edition. * Sensitizing EGFR mutation: EGFR exon 19 deletion or EGFR L858R. * Age 18-75 years. * Karnofsky Performance Status score ≥70. * Complete whole-body imaging assessment before initiation of first-line third-generation EGFR-TKI plus chemotherapy, with at least one evaluable lesion according to RECIST version 1.1. * No disease progression after completion of four cycles of first-line third-generation EGFR-TKI plus chemotherapy and no unresolved grade ≥3 nonhematologic toxicity. * Oligo-residual disease after four treatment cycles, with all residual lesions considered suitable for stereotactic radiotherapy by the investigator. * Written informed consent. Exclusion Criteria: * Double primary or multiple primary malignancies, except early skin cancer or cervical carcinoma in situ treated with curative intent and without recurrence or progression for at least five years. * Pregnancy or breastfeeding, or considered unsuitable by the investigator for PET/CT or brain MRI examination. * History of uncontrolled epilepsy, central nervous system disease, or psychiatric disorder that, in the investigator's judgment, may interfere with informed consent or participant compliance. * Residual lesions considered unsuitable for consolidative stereotactic radiotherapy after first-line third-generation EGFR-TKI plus chemotherapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-mutant non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug takes aim at ROS1-Positive lung cancer in Head-to-Head trial
- Can five radiation doses replace weeks of treatment for endometrial cancer?
- Can a Two-Drug combo outsmart tough lung cancer?
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Double-Drug attack: new combo aims to tackle tough lung cancer
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers